AngioDynamics News

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot burden AngioDynamics,

BusinesswireMay 6 15:45

Oppenheimer Predicts Over 100% Rally for These 2 Healthcare Stocks

Yahoo FinanceMay 1 23:34

CEO, President & Director of AngioDynamics Picks Up 2.6% More Stock

Whilst it may not be a huge deal, we thought it was good to see that the AngioDynamics, Inc. (NASDAQ:ANGO) CEO, President & Director, James Clemmer, recently bought US$67k worth of stock, for US$6.70 per share.

Simply Wall StApr 12 13:40

AngioDynamics, Inc. (NASDAQ:ANGO) Stock Catapults 25% Though Its Price And Business Still Lag The Industry

AngioDynamics, Inc. (NASDAQ:ANGO) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses o

Simply Wall StApr 11 05:55

Insider Spends US$67k Buying More Shares In AngioDynamics

Yahoo FinanceApr 10 05:16

Insiders Buying Zumiez And 3 Other Stocks

Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view

BenzingaApr 9 06:29

AngioDynamics(ANGO.US) Officer Buys US$67,000 in Common Stock

$AngioDynamics(ANGO.US)$ Officer Clemmer James C purchased 10,000 shares of common stock on Apr 8, 2024 at an average price of $6.7 for a total value of $67,000.Source: Announcement What is statement

Futu NewsApr 8 16:13

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript

Yahoo FinanceApr 8 08:26

Earnings Call: AngioDynamics Posts Mixed Q3 Results, Focuses on Growth

AngioDynamics (ticker: NASDAQ:ANGO), a medical device company, reported varied results in its fiscal year 2024 third-quarter earnings call.

Investing.com Apr 8 04:28

AngioDynamics Third Quarter 2024 Earnings: Misses Expectations

Yahoo FinanceApr 6 08:58

AngioDynamics Inc (ANGO) Q3 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst ...

Yahoo FinanceApr 5 16:44

Ocugen OCGN Phase 1⁄2 DSMB; AngioDynamics ANGO Analysts

BioPharmCatalystApr 5 13:21

AngioDynamics Shares Are Trading Higher After Oppenheimer Upgraded the Stock From Perform to Outperform and Announced a $12 Price Target.

AngioDynamics Shares Are Trading Higher After Oppenheimer Upgraded the Stock From Perform to Outperform and Announced a $12 Price Target.

BenzingaApr 5 12:53

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

Yahoo FinanceApr 5 10:52

AngioDynamics Raised to Outperform From Perform by Oppenheimer

AngioDynamics Raised to Outperform From Perform by Oppenheimer

Dow JonesApr 5 07:50

Oppenheimer Upgrades AngioDynamics to Outperform, Announces $12 Price Target

Oppenheimer analyst Steven Lichtman upgrades AngioDynamics from Perform to Outperform and announces $12 price target.

Analyst UpgradesApr 5 07:40

AngioDynamics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 76.73% Oppenheimer → $12 Upgrades Perform → Outperform 01/09/2024 47.28% Raymond James $12 → $1

BenzingaApr 5 07:39

ATOS, SMR and EIGR Are Among Pre Market Gainers

Seeking AlphaApr 5 07:34

AngioDynamics Stock Upgraded by Oppenheimer on FDA Approval, Strong Balance Sheet

InvestingApr 5 07:16

FDA Clears AngioDynamics' AlphaVac F18 to Treat Pulmonary Embolism

MassDeviceApr 5 06:24